Literature DB >> 6553561

New synthetic inhibitor to the alternative complement pathway.

N Ikari, Y Sakai, Y Hitomi, S Fujii.   

Abstract

The inhibitory effects of 6-amidino-2-naphthyl 4-guanidinobenzoate (FUT-175) on the activities of factor B, factor D and cobra venom factor (CVF) X Bb were examined. FUT-175 bound specifically to the Bb fragment of factor B or CVF X Bb. FUT-175 was a non-competitive inhibitor of the esterolysis of L-leucyl-L-alanyl-L-arginine naphthylester by factor B and CVF X Bb. FUT-175 also inhibited the haemolytic activity of factor B, the C3 convertase activity of CVF X Bb and the factor B-cleaving activity of factor D. The concentration of FUT-175 causing 50% inhibition of these activities was 10(-5) - 10(-4)M.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6553561      PMCID: PMC1454324     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  18 in total

1.  The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways.

Authors:  R G Medicus; O Götze; H J Müller-Eberhard
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

2.  Complement activation by the properdin system: formation of a stoichiometric. C3 cleaving complex of properdin factor B with C36.

Authors:  W Vogt; W Dames; G Schmidt; L Dieminger
Journal:  Immunochemistry       Date:  1977-03

3.  Inhibition of the classical and alternative pathways by amino acids and their derivatives.

Authors:  Y Takada; Y Arimoto; H Mineda; A Takada
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

4.  Leupeptin inhibits the C3/5 convertase CVFBb of the complement system.

Authors:  L H Caporale
Journal:  Biochim Biophys Acta       Date:  1981-07-24

5.  Partial sequence of human complement component factor B: novel type of serine protease.

Authors:  D L Christie; J Gagnon; R R Porter
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

6.  Purification and some properties of factor D of the human properdin system.

Authors:  L Dieminger; W Vogt; R Lynen
Journal:  Z Immunitatsforsch Immunobiol       Date:  1976-11

7.  The alternative pathway C3/C5 convertase: chemical basis of factor B activation.

Authors:  P H Lesavre; T E Hugli; A F Esser; H J Müller-Eberhard
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

8.  An improved method for the isolation from Naja naja venom of cobra factor (CoF) free of phospholipase A.

Authors:  M B Pepys; C Tompkins; A D Smith
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

9.  Third component of human complement: appearance of a sulfhydryl group following chemical or enzymatic inactivation.

Authors:  J Janatova; P E Lorenz; A N Schechter; J W Prahl; B F Tack
Journal:  Biochemistry       Date:  1980-09-16       Impact factor: 3.162

10.  Structural evidence that complement factor B constitutes a novel class of serine protease.

Authors:  J E Mole; M A Niemann
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

View more
  15 in total

1.  An anti-coagulation agent Futhan preferentially targets GABA(A) receptors in lungepithelia: implication in treating asthma.

Authors:  Xuanmao Chen; Minghua Li; Zhi-Gang Xiong; Beverley A Orser; John F Macdonald; Wei-Yang Lu
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-11-15

2.  Complement activation is involved in biological responses to leukocyte adsorptive apheresis.

Authors:  Shoichi Nishise; Yuji Takeda; Hiroaki Takeda; Katsuyoshi Ishihama; Tadahisa Fukui; Sumio Kawata
Journal:  Dig Dis Sci       Date:  2006-04-27       Impact factor: 3.199

3.  The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart.

Authors:  Laura R La Bonte; Betsy Dokken; Grace Davis-Gorman; Gregory L Stahl; Paul F McDonagh
Journal:  Diab Vasc Dis Res       Date:  2009-07       Impact factor: 3.291

4.  Small-molecule factor D inhibitors targeting the alternative complement pathway.

Authors:  Jürgen Maibaum; Sha-Mei Liao; Anna Vulpetti; Nils Ostermann; Stefan Randl; Simon Rüdisser; Edwige Lorthiois; Paul Erbel; Bernd Kinzel; Fabrice A Kolb; Samuel Barbieri; Julia Wagner; Corinne Durand; Kamal Fettis; Solene Dussauge; Nicola Hughes; Omar Delgado; Ulrich Hommel; Ty Gould; Aengus Mac Sweeney; Bernd Gerhartz; Frederic Cumin; Stefanie Flohr; Anna Schubart; Bruce Jaffee; Richard Harrison; Antonio Maria Risitano; Jörg Eder; Karen Anderson
Journal:  Nat Chem Biol       Date:  2016-10-24       Impact factor: 15.040

5.  Structure, function, and pharmacology of acid-sensing ion channels (ASICs): focus on ASIC1a.

Authors:  Stefan Gründer; Xuanmao Chen
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-03-18

6.  Survival of Carbapenem-Resistant Klebsiella pneumoniae Sequence Type 258 in Human Blood.

Authors:  Frank R DeLeo; Scott D Kobayashi; Adeline R Porter; Brett Freedman; David W Dorward; Liang Chen; Barry N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

7.  A blockade of complement activation prevents rapid intestinal ischaemia-reperfusion injury by modulating mucosal mast cell degranulation in rats.

Authors:  T Kimura; A Andoh; Y Fujiyama; T Saotome; T Bamba
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

8.  Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice.

Authors:  S Ikehara; K Shimamura; T Aoyama; S Fujii; Y Hamashima
Journal:  Immunology       Date:  1985-08       Impact factor: 7.397

9.  In vitro and in vivo gene delivery by recombinant baculoviruses.

Authors:  Hideki Tani; Chang Kwang Limn; Chan Choo Yap; Masayoshi Onishi; Masami Nozaki; Yoshitake Nishimune; Nobuo Okahashi; Yoshinori Kitagawa; Rie Watanabe; Rika Mochizuki; Kohji Moriishi; Yoshiharu Matsuura
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors.

Authors:  M Takeyama; T Ishida; N Kokubu; F Komada; S Iwakawa; K Okumura; R Hori
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.